Sartorius shows demand recovery with stronger cash conversion
Sartorius reported 8.1% constant-currency operational sales growth excluding U.S. tariff compensation for the first nine months of 2026, alongside a 55.2% increase in free cash flow.
Supply-chain research brief
AI Biotech Infrastructure
Map sequencing, automation, instruments, bioprocessing, compute, data, and scale-up infrastructure for AI-native biotech.
Company announcements
Results and delivery schedules
Company disclosures and calendar updates have their own source dates. They do not revalidate every supplier role in this sector.
Market map
Where constraints can shape the market
AI-native biology is constrained by the cost, quality, and throughput of experimental feedback. Models need sequence and assay data, automated laboratories, reliable instruments, reagents, sample handling, bioprocessing, and compute. A digital prediction has limited value until a physical experiment can validate it and a process can reproduce it at scale.
The directory separates sequencing and omics, laboratory automation, bioprocessing consumables, cloud and data infrastructure, AI drug-discovery platforms, CRO/CDMO scale-up, and synthetic-biology screening. This distinguishes enabling infrastructure from drug developers whose economics remain tied to individual clinical assets.
Evidence is weighted by maturity: an official product or platform page supports technical relevance; a named collaboration supports workflow adoption; reported instrument placements, consumables growth, backlog, or manufacturing agreements provide stronger economic validation. Unreported AI-biotech revenue is not presented as fact.
Source-backed research
Recent notes for this research universe
Versioned notes keep public evidence and member-only interpretation separate while preserving one canonical source.
NVIDIA maps the capacity queue beyond HBM
NVIDIA disclosed dated capacity agreements across substrates, advanced packaging, testing and optical engines on October 21. The figures are supplier targets and reservations, not commissioned or customer-accepted output.
Research universe
Supply-chain layers we track
- Sequencing & Omics4 tracked companies
- Lab Automation & Instruments9 tracked companies
- Bioprocessing & Consumables5 tracked companies
- Cloud, Compute & Data4 tracked companies
- AI Drug Discovery Platforms4 tracked companies
- CRO, CDMO & Scale-up3 tracked companies
- Synthetic Biology & Screening2 tracked companies
Public preview
Five representative companies in the research universe
Examples are sampled across supply-chain layers; ordering is not a ranking. Each date records the company’s supplier-role review, not a new review of its financials or investment thesis. The sector date above does not mean every company was reviewed together. Scores, thesis, risks and full evidence remain in the Atlas.
10x Genomics
TXG · NASDAQ
Supply-chain layerSingle-cell and spatial biology
Evidence status: Verified · Supplier role reviewed 2026-08-22
Agilent Technologies
A · NYSE
Supply-chain layerAnalytical instruments and laboratory software
Evidence status: Sourced · Supplier role reviewed 2026-08-22
Avantor
AVTR · NYSE
Supply-chain layerLaboratory and bioprocessing materials
Evidence status: Sourced · Supplier role reviewed 2026-08-22
Alphabet
GOOGL · NASDAQ
Supply-chain layerCloud, models and biological data platforms
Evidence status: Verified · Supplier role reviewed 2026-08-22
AbCellera Biologics
ABCL · NASDAQ
Supply-chain layerAntibody discovery platform and screening
Evidence status: Verified · Supplier role reviewed 2026-08-22
Open supplier research
AI biotech infrastructure companies: laboratory, data and scale-up
AI-native biology needs reproducible experimental feedback. Separate laboratory instruments and automation, data and compute, and validated bioprocess scale-up before comparing companies. Company-wide revenue is not AI-specific infrastructure revenue.
Laboratory automation and instruments
Ask whether a workflow is validated, routinely used and producing reproducible assays. A product launch does not quantify installed capacity or utilization.
Biological data and compute
Distinguish model performance and cloud availability from standardized experimental data. Compute capacity alone does not prove reliable biological feedback.
Bioprocessing and scale-up
Track process validation, qualified consumables and accepted production. Experimental success and manufacturing readiness require different evidence.
| Company / ticker | Industrial role | What public evidence establishes | Sources and dates |
|---|---|---|---|
| Thermo Fisher Scientific TMO | Single-use bioprocessing equipment and scientific instruments | Thermo Fisher describes single-use bioreactors, mixers, chromatography and harvest systems with automation. |
|
| Agilent Technologies A | LC/HRMS instruments and biopharma quality-control workflows | Agilent launched a multi-attribute workflow combining LC/HRMS instrumentation, software, columns and standards for biopharma QC. |
|
| Danaher DHR | Bioprocessing equipment and consumables through Cytiva | Danaher identifies Cytiva, including the Pall Life Sciences business, within its biotechnology portfolio. |
|
| Repligen RGEN | Filtration, chromatography and process analytics | Repligen describes filtration systems, pre-packed chromatography columns, fluid management and process analytics for biologics. |
|
| Sartorius SRT | Chromatography systems and single-use bioprocess tools | Sartorius reported nine-month operational sales growth, recovering bioprocess equipment and instrument demand, and stronger cash conversion alongside its chromatography and single-use portfolio. |
|
| Lonza Group LONN | Contract biologics manufacturing and process transfer | Lonza describes Vacaville as a cGMP mammalian site with 12,000 L and 25,000 L reactors and 332,000 L of stated capacity. |
|
Selection is illustrative and not a ranking. Read each profile for counter-evidence and economic limits; missing customer relationships, qualified output and theme-specific revenue remain unknown.
Full research access
Open all 31 companies, scores, risks, and sources.
Verify your email to use the filterable directory and review the complete evidence-backed research set.
Questions
How to read this market
What is the core AI-biotech bottleneck?
The experiment loop: generating standardized biological data, automating assays, learning from results, and translating a candidate into reproducible manufacturing.
Why include diversified tool vendors?
A diversified instrument or consumables supplier can control a critical workflow despite low pure-play exposure, so bottleneck relevance is scored separately.
Are AI drug developers infrastructure companies?
Only when their platforms generate reusable data or workflow capacity. Pipeline value and platform value are separated in the thesis and risk assessment.